Early Breast Cancer Genetic Testing Pathway for Familial Risk and Treatment Purposes: Solutions Toolkit

This toolkit is designed to support the implementation of g*BRCA* testing in your treatment pathway. The resources provided here to support you were identified during discussions held at several meetings of the AstraZeneca funded and organised BRCA Testing UK Steering Committee between May 2022 and September 2023.*

Click the relevant section of the potential pathway ‘pinch point’ to access the resources to address common challenges:

1. **Capturing information on family history**
2. **Identifying eligible patients at MDT meetings**
3. **Main-streaming**
4. **Genetic testing**
5. **Treatment decision and genetic counselling**

View the UKBCG, ABS and UKCGG reviewed pathway as a template for your service



This toolkit has been developed and funded by AstraZeneca and is intended for Healthcare Professionals in the UK

*The Steering Committee was a multidisciplinary group of HCPs working in the NHS, including expert representatives from the fields of breast surgery, oncology, nursing, genetics, pathology and clinical science.

ABS: Association of Breast Surgery; BRCA: breast cancer susceptibility gene; g*BRCA*: germline breast cancer susceptibility gene; HCP: healthcare professional; MDT: multidisciplinary team; NHS: National Health Service; UK: United Kingdom; UKBCG: UK Breast Cancer Group; UKCGG: UK Clinical Genetics Group

GB-71262
Date of preparation: October 2025

Capturing information on family history

Accurately capturing family history helps you to see the full background of a patient to inform their treatment plan. Here are some external resources that can support you:

Access NHS training resources on the importance and delivery of genomic testing

Genomics Education Programme

The CanRisk tool supports calculating a patients eligibility for genomic testing

CanRisk website

Use patient facing online questionnaires to support completion of family history

St Georges Family History Questionnaire*

Support patients with leaflets and information sheets on genomic testing e.g.

The Royal Marsden

South West Genomic Laboratory Hub

Implement a Genomic Practitioner into your pathway#

Genomic Practitioner#

* Can be used to automatically generate CanRisk input files and scores; it can be made available to other centres via a licensing agreement with St George's University Hospitals NHS Foundation Trust. Please contact **stgh-tr.genomicservices@nhs.net** for further information.

Email AZDiagnostics@astrazeneca.com for support and information on how this role has been implemented

Identifying eligible patients at MDT meetings

Identifying all patients eligible for genomic testing is a challenge but can impact your treatment decisions for your patients. Here are some external resources that can support you:

The CanRisk tool supports calculating a patients eligibility for genomic testing

CanRisk website

The QGenome app can help match genomic tests available to your patients

QGenome app

Utilise the Manchester scoring tools within the GeNotes hub

Pathologically Adjusted Manchester scoring

View the latest funded genomic tests e.g. R208 / R444.1 gBRCA testing

National Genomic Testing Directory

Implement a Genomic Practitioner into your pathway#

Genomic Practitioner#

Use the GeNotes knowledge hub for patient case studies

GeNotes Oncology Hub

Helpful tips

- Dedicate a portion of the MDT meeting to determining each patient's eligibility for genetic testing and nominate colleagues to lead on genetic testing identification
- Adapt the MDT form to include a standardised pre-meeting pro forma covering eligibility for genetic testing, to be filled out by the clinician who is requesting the patient be discussed
- Ensure that, if possible, a representative from clinical genetics is in attendance at all MDT meetings, or at least the portion of the MDT meetings when genetic testing is discussed
- #If your service cannot implement a Genomic Practitioner role, other services have implemented a 'Genetic Champion' within their MDT who can flag patients eligible for genetic testing to ensure all patients are identified

Email AZDiagnostics@astrazeneca.com for support and information on how this role has been implemented

Mainstreaming

Mainstreaming can support your service with embedding genomic testing without a dramatic change in the management of your patients. Here are some external resources that can support you:

Use the UKBCG, ABS and CGG reviewed pathway as a template for your service

BRCA testing pathway

The Talking about Risk, Uncertainties of Testing in Genetics (TRUSTING) programme can upskill your patient discussions

TRUSTING educational workshops

Take the Nucleus Medics Academy mainstreaming course*

Nucleus Medics Academy

Use patient resources to support consenting and informing for genetic testing e.g.

BRCA Genes and Me#

The Royal Marsden

South West Genomic Laboratory Hub

Use the GeNotes knowledge hub mainstreaming resources

GeNotes Oncology Hub

* Nucleus Medics Academy is a paid-for subscription upon sign-up

The "BRCA Genes & Me" project in the South West Genomic Medicine Service Alliances (GMSA) has created a series of educational videos explaining genetic testing, with an option to capture online consent, thereby alleviating pressure from clinicians. Please contact Tracie Miles (tracie.miles@nhs.net) for any questions or comments

Genetic testing

The timely return of genomic test results* is crucial to ensure they are available in time for your treatment decisions. Here are some external resources that can support you:

Request forms for your GLH are available online

Access genomic test request forms for all GLHs

Ensure all required information is provided with your request

Guidance for how to complete a request form

View the latest funded genomic tests e.g. R208 / R444.1 gBRCA testing

National Genomic Testing Directory

Suggested tips for delays in turnaround times:

- Ensure the priority of your test is clearly marked when submitted – and informing a treatment decision
- Ensure there is enough clinical information on the test request form to allow the lab to accurately triage your request
- Provide central mailboxes for results to be sent to ensure continuity in the receipt and processing of results

* ≤42 days (NHS turnaround target for laboratories conducting a standard, non-urgent genetic test).

GLH: Genomic Laboratory Hub

Treatment decision and genetic counselling

Communicating with patients on the rationale for genetic testing and results can be challenging. Here are some external resources that can support you:

Use patient resources to support consenting and informing for genetic testing e.g.

BRCA genes and me videos*

Support patients with leaflets and information sheets on genomic testing e.g.

The Royal Marsden

South West Genomic Laboratory Hub

Use the UKBCG, ABS and CGG reviewed pathway to ensure genetic referrals are implemented when required

BRCA testing pathway

Implement a Genomic Practitioner into your pathway#

Genomic Practitioner#

*The "BRCA Genes & Me" project in the South West GMSA has created a series of educational videos explaining genetic testing, with an option to capture online consent, thereby alleviating pressure from clinicians. Please contact Tracie Miles (tracie.miles@nhs.net) for any questions or comments

#Email AZDiagnostics@astrazeneca.com for support and information on how this role has been implemented

Disclaimers

The information in this toolkit is non-promotional and has been provided to you as per your request following engagement with your local AstraZeneca representative.

This toolkit must only be used for your own personal information and education.

This toolkit contains links to useful external websites. AstraZeneca has no responsibility or control over the content of these sites, and it has not contributed to the creation of the content of these sites unless otherwise specified. The links are provided for your information only.

Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/

Adverse events should also be reported to AstraZeneca on 0800 783 0033 or via: https://aereporting.astrazeneca.com



Capturing information on family history | Identifying eligible patients at MDT meetings | Main-streaming | Genetic testing | Treatment decision and genetic counselling

GB-71262
Date of preparation: October 2025